Sagent Pharmaceuticals Announces Offering Of 4,441,627 Shares Of Common Stock

SCHAUMBURG, Ill., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced an offering of shares of common stock. The Company will be offering 3,384,097 shares of common stock and selling shareholders will be offering 1,057,530 shares of common stock. In addition, selling shareholders, collectively, intend to grant the underwriters a 30-day option to purchase up to an additional 666,244 shares of common stock, all at the public offering price less the underwriter discount.

The Company intends to use the net proceeds for general corporate purposes, which it expects to include funding working capital, operating expenses, the continued development of its product pipeline and portfolio, the maintenance and expansion of its current collaboration arrangements, the strengthening of its existing commercial organization, funding the final payments for the remaining 50% interest in Sagent (China) Pharmaceuticals Co. Ltd. and any costs related to its manufacturing facility, and the selective pursuit of business development opportunities in its focus segment areas. The Company will not receive any of the proceeds from the sale of shares by the selling stockholders, including the shares to be sold by the selling stockholders if the underwriters exercise their over-allotment option.

Morgan Stanley, Jefferies and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Piper Jaffray & Co. and Needham & Company, LLC are acting as co-managers. The offering will be made only by means of a written prospectus, copies of which may be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 (Phone: 866-718-1649, Email: prospectus@morganstanley.com), Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022 (Phone: 877-547-6340, Email: Prospectus_Department@Jefferies.com), or from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038 (Email: dg.prospectus_requests@baml.com).

The shares of common shares are being sold pursuant to the Company's existing effective shelf registration statement on file with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

If you liked this article you might like

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Sagent Pharmaceuticals (SGNT) Soared Today on Nichi-Iko Deal

3 Stocks You Might Want to Sell Now

Sagent Pharmaceuticals (SGNT) Flagged As Strong On High Volume